Bridging the gap: A hybrid model to link efficacy and effectiveness research in substance abuse treatment

Psychiatric Services

Volumn 54, Issue 3, 2003, Pages 333-339

  Carroll, Kathleen M ^a,b   Rounsaville, Bruce J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; NALTREXONE; NICOTINE;

ALCOHOLISM; BEHAVIOR THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG DEPENDENCE; HEALTH CARE DELIVERY; HUMAN; MEDICAL RESEARCH; MODEL; OPIATE ADDICTION; PATIENT SATISFACTION; PHYSICIAN; REVIEW; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; TREATMENT OUTCOME; ADDICTION; CLINICAL TRIAL; COOPERATION; COST BENEFIT ANALYSIS; EVIDENCE BASED MEDICINE; METHODOLOGY; NONBIOLOGICAL MODEL; OUTCOME ASSESSMENT; UNITED STATES;

CLINICAL TRIALS; COOPERATIVE BEHAVIOR; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HUMANS; MODELS, ORGANIZATIONAL; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; RESEARCH DESIGN; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; UNITED STATES;

EID: 0037358711     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.54.3.333     Document Type: Review

References (67)

1. Beutler LE, Howard KI: Clinical utility research: an introduction. Journal of Clinical Psychology 54:297-301, 1998
2. Norquist G, Lebowitz B, Hyman S: Expanding the frontier of treatment research. Prevention and Treatment 2, 1999. Available at www.journals.apa.org/prevention/volume2/pre0020001a.html
3. Wells KB: Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. American Journal of Psychiatry 156:5-10, 1999
4. Institute of Medicine: Bridging the Gap Between Practice and Research: Forging Partnerships With Community-Based Drug and Alcohol Treatment. Washington, DC, National Academy Press, 1998
5. Sees KL, Delucchi KL, Masson C, et al: Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 283:1303-1310, 2000
6. Barnett PG: The cost-effectiveness of methadone maintenance as a health care intervention, Addiction 94:479-488, 1999
7. Barnett PG, Hui SS: The cost-effectiveness of methadone maintenance. Mount Sinai Journal of Medicine 5:365-374, 2000
8. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction: Effective medical treatment of opiate addiction. JAMA 280:1936-1943, 1998
9. Rounsaville BJ, Kosten TR: Treatment for opioid dependence: quality and access. JAMA 283:1337-1339, 2000
10. McCarty D, Frank RG, Denmead GC: Methadone maintenance and state Medicaid managed care programs. Milbank Quarterly 77:341-362, 1999
11. Ball JC, Ross A: The Effectiveness of Methadone Maintenance Treatment. New York, Springer-Verlag, 1991
12. O'Brien CP: A range of research-based pharmacotherapies for addiction. Science 278:66-70, 1997
13. McLellan AT, McKay JR: The treatment of addiction; what can research offer practice? in Bridging the Gap Between Practice and Research: Forging Partnerships With Community Based Drug and Alcohol Treatment. Edited by Lamb S, Greenlick MR, McCarty D. Washington DC, National Academy Press, 1998
14. Miller WR, Brown JM, Simpson TL, et al: What works? A methodological analysis of the alcohol treatment literature, in Handbook of Alcoholism Treatment Approaches: Effective Altematives. Edited by Hester RK, Miller WR. Boston, Mass, Allyn & Bacon, 1995
15. McLellan AT, Grossman DS, Blaine JD, et al: Acupuncture treatment for drug abuse: a technical review. Journal of Substance Abuse Treatment 10:569-576, 1993
16. Horgan CM, Levine HJ: The substance abuse treatment system: what does it look like and whom does it serve? in Bridging the Gap Between Practice and Research: Forging Partnerships With Community-Based Drug and Alcohol Treatment. Edited by Lamb S, Greenlick MR, McCarty D. Washington, DC, National Academy Press, 1999
17. Rounsaville BJ, Carroll KM, Onken LS: A stage model of behavioral therapies research: getting started and moving on from stage I. Clinical Psychology: Science and Practice 8:133-142, 2001
18. Prien RF, Robinson DS: Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. New York, Raven, 1994
19. Institute of Medicine: Small Clinical Trials: Issues and Challenges. Washington, DC, National Academy Press, 2001
20. Budney AJ, Higgins ST: A Community Reinforcement Plus Vouchers Approach: Treating Cocaine Addiction. Rockville, Md, National Institute on Drug Abuse, 1998
21. Higgins ST, Delany DD, Budney AJ, et al: A behavioral approach to achieving initial cocaine abstinence. American Journal of Psychiatry 148:1218-1224, 1991
22. Silverman K, Higgins ST, Brooner RK, et al: Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Archives of General Psychiatry 53:409-415, 1996
23. Milby JB, Schumacher JE, Raczynski JM, et al: Sufficient conditions for effective treatment of substance abusing homeless persons. Drug and Alcohol Dependence 43:39-47, 1996
24. Kirby KC, Marlowe DB, Festinger DS, et al: Schedule of voucher delivery influences initiation of cocaine abstinence. Journal of Consulting and Clinical Psychology 66:761-767, 1998
25. Carroll KM, Ball SA, Nich C, et al: Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Archives of General Psychiatry 58:755-761, 2001
26. Preston KL, Silverman K, Umbricht A, et al: Improvement in naltrexone treatment compliance with contingency management. Drug and Alcohol Dependence 54:127-135, 1999
27. Griffith JD, Rowan-Szal GA, Roark RR, et al: Contingency management in outpatient methadone treatment: a meta-analysis. Drug and Alcohol Dependence 58:55-66, 2000
28. Petry NM, Martin B, Cooney JL, et al: Give them prizes and they will come: contingency management treatment of alcohol dependence. Journal of Consulting and Clinical Psychology 68:250-257, 2000
29. Petry NM, Martin B: Low-cost contingency management for treating cocaine- and opioid abusing methadone patients. Journal of Consulting and Clinical Psychology 70:398-405, 2002
30. Sacon AJ, Calsyn DA, Haver VM, et al: A nationwide survey of urinalysis practices of methadone maintenance clinics: utilization of laboratory services. Archives of Pathology and Laboratory Medicine 114:94-100, 1990
31. Kessler RC, Zhao S, Katz SJ, et al: Past-year use of outpatient services for psychiatric problems in the National Comorbidity Study. American Journal of Psychiatry 156:115-123, 1999
32. Regier DA, Narrow WE, Rae DS, et al: The defacto US mental health and addictive disorders service system: Epidemiological Catchment Area prospective one-year prevalence rates of disorders and services. Archives of General Psychiatry 50:85-91, 1993
33. Norquist G, Regier DA: The epidemiology of psychiatric disorders and the de facto mental health care system. Annual Review of Medicine 47:473-479, 1996
34. O'Malley SS, Jaffe AJ, Chang G, et al: Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Archives of General Psychiatry 49:881-887, 1992
35. Volpicelli JR, Alterman AI, Hayashida M, et al: Naltrexoiie in the treatment of alcohol dependence. Archives of General Psychiatry 49:876-880, 1992
36. O'Malley SS, Croop RS, Wroblewski JM, et al: Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatric Annals 25:681-688, 1995
37. Croop RS, Falkner EB, Lagriola DF, et al: The safety profile of naltrexone in the treatment of alcoholism: results from a multicenter usage study. Archives of General Psychiatry 54:1130-1135, 1997
38. Regier DA, Farmer ME, Rae DS, et al: Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 264:2511-2518, 1990
39. Kessler RC, Crum RM, Warner LA, et al: Lifetime co-occurenee of DS M-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Study. Archives of General Psychiatry 54:313-321, 1997
40. Kessler RC, McGonagle KA, Zhao S, et al: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Study. Archives of General Psychiatry 51:8-19, 1994
41. Fuller RK, Branchey L, Brightwell DR, et al: Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 256:1449-1455, 1986
42. Rychtarik RG, Connors GJ, Derman KH, et al: Alcoholics Anonymous and the use of medications to prevent relapse: an anonymous survey of member attitudes. Journal of Studies on Alcohol 61:134-138, 2000
43. Gonzalez JE Brogden RN: Naltrexone: review of its pharmacodymamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35:192-213, 1988
44. Humphreys K, Weisner C: Use of exclusion criteria in selecting research subjects and its effect on the generalizability of alcohol treatment outcome studies. American Journal of Psychiatry 157:588-594, 2000
45. Carroll KM, Nich C, McLellan AT, et al: Research versus real world patients: representativeness of subjects participating in clinical trials of treatments for cocaine dependence. Drug and Alcohol Dependence 54:171-177, 1997
46. Donenberg GR, Lyons JS, Howard KI: Clinical trials versus mental health services research: contributions and connections. Journal of Clinical Psychology 55:1135-1145, 1999
47. Borkovee TD, Echemendia RJ, Ragusea SA, et al: The Pennsylvania Practice Research Network and future possibilities for clinically meaningful and scientifically rigorous psychotherapy effectiveness research. Clinical Psychology: Science and Practice 8:155-167, 2001
48. McLellan AT, Arndt IO, Metzger D, et al: The effects of psychosocial services in substance abuse treatment. JAMA 269:1953-1959, 1993
49. Klein DF, Smith LB: Organizational requirements for effective clinical effectiveness studies. Prevention and Treatment 2, 1999. Available at www.journals.apa.org /prevention/volume2/pre0020002a.html
50. Carise D, McLellan AT, Gifford LS, et al: Developing a national addiction treatment information system: an introduction to the Drug Evaluation Network System. Journal of Substance Abuse Treatment 17:67-77, 1999
51. Carroll KM, Connors GJ, Cooney NL, et al: Internal validity of Project MATCH treatments: discriminality and integrity. Journal of Consulting and Clinical Psychology 66:290-303, 1998
52. Crits-Christoph P, Siqueland L, Chittams J, et al: Training in cognitive, supportive-expressive, and drug counseling therapies for cocaine dependence. Journal of Consulting and Clinical Psychology 66:484-492, 1998
53. Rounsaville BJ, Chevron E, Weissman MM, et al: Training therapists to perform interpersonal psychotherapy in clinical trials. Comprehensive Psychiatry 2%364-371, 1986
54. Crits-Christoph P, Baranackie K, Kurcias J, et al: Meta-analysis of therapist effects in psychotherapy outcome studies. Psychotherapy Research 1:81-91, 1991
55. DeRubeis RJ, Hollon SD, Evans MD, et al: Can psychotherapies for depression be discriminated? A systematic evaluation of cognitive therapy and interpersonal psychotherapy. Journal of Consulting and Clinical Psychology 50:144-756, 1982
56. Hill CE, O'Grady KE, Elkin I: Applying the Collaborative Study Psychotherapy Rating Scale to rate therapist adherence in cognitive-behaioral therapy, interpersonal therapy, and clinical management. Journal of Consulting and Clinical Psychology 60:73-79, 1992
57. Kraft MK, Bothbard AB, Hadley TR, et al: Are supplementary services provided during methadone maintenance really cost-effective? American Journal of Psychiatry 154:1214-1219, 1997
58. Avants SK, Margolin A, Sindelar JL, et al: Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. American Journal of Psychiatry 156:27-33, 1999
59. Rosenheek RA, Kosten TR: Buprenorphine for opiate addiction: potential economic impact. Drug and Alcohol Dependence 63:253-262, 2001
60. Holder HD, Cisler RA, Longabaugh R, et al: Alcoholism treatment and medical care costs for Project MATCH. Addiction 95:999-1013, 2000
61. Svikis DS, Golden AS, Guggins GR, et al: Cost-effectiveness of treatment for drug-abusing pregnant women. Drug and Alcohol Dependence 45:105-113, 1997
62. Kazdin AE: Comparative outcome studies of psychotherapy: methodological issues and strategies. Journal of Consulting and Clinical Psychology 54:95-105, 1986
63. MeLellan AT, Hunkeler E: Patient satisfaction and outcomes in alcohol and drug abuse treatment. Psychiatric Services 49:573-575, 1998
64. Holcomb WR, Parker JC, Leong GB, et al: Customer satisfaction and self-reported treatment outcomes among psychiatric in patients. Psychiatric Services 49:1622-1623, 1998
65. Rohland BM, Langbehn DR, Rohrer JE: Relationship between service effectiveness and satisfaction among persons receiving Medicaid mental health services. Psychiatric Services 51:248-250, 2000
66. Donovan DM, Kadden RM, DiClemente CC, et al: Client satisfaction with three therapies in the treatment of alcohol dependence: results from Project MATCH. American Journal on Addictions 11:291-307, 2002
67. McLellan AT, Belding MA, McKay JR, et al: Can the outcomes research literature inform the search for quality indicators in substance abuse treatment? in Managing Managed Care: Quality Improvement in Behavioral Health. Edited by Edmunds M, Frank RG, Hogan M, et al. Washington, DC, National Academy Press, 1996